Updated

Novo Nordisk discontinued two more clinical trials for cardiovascular drug candidates, adding to a string of pipeline setbacks for the Danish pharmaceutical giant. The move comes as the company faces intensifying competition in metabolic and cardiovascular disease treatment from rivals including Eli Lilly. The trial discontinuations raise questions about the depth of Novo Nordisk's cardiovascular pipeline beyond its core GLP-1 franchise, though the company has not detailed the specific reasons for halting the studies.